Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers

Recruiting

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

France

CHRU Amiens, Amiens